Browse by category

Fractyl expands ERASE Task Force to study underlying GLP-1-based pancreatic gene therapy for T2DM

Fractyl Health has expanded an academic-industry scientific partnership charged with advancing research on the role of the gut and...

Carmot begins Phase 2 trial of dual GLP-1/GIP RA CT-868 for the treatment of type 1 diabetes

Carmot Therapeutics has commenced a Phase 2 clinical trial of its once-daily dual GLP-1/GIP receptor agonist, CT-868, in adult...

People with obesity burn less energy during day

A study by researcher at Oregon Health & Science University has found people who have a healthy weight use more energy during the day,...

Journal Watch 15/11/2023

Welcome to our weekly round-up of the latest bariatric and obesity-related papers published in the medical literature. As ever, we have...

Updates on banded procedure studies and randomised controlled trials

At the recent International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) World Congress in Naples, Italy,...

SELECT: Semaglutide reduces CV events in non-diabetic patients with overweight or obesity

Semaglutide 2.4mg (Wegovy) reduces cardiovascular events in patients with overweight or obesity and pre-existing cardiovascular disease...

US obesity organisations call for better testing and labelling of drugs for people with obesity

Semaglutide associated with reductions in alcohol use disorder symptoms

Journal Watch 29/11/2023

Weekly Digest